This site became the new ClinicalTrials.gov on June 19th. Learn more.
Show more
ClinicalTrials.gov Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu
Give us feedback

Genetic Susceptibility to Bladder Cancer

This study is currently recruiting participants.
See Contacts and Locations
Verified April 2017 by M.D. Anderson Cancer Center
Sponsor:
Collaborator:
National Cancer Institute (NCI)
Information provided by (Responsible Party):
M.D. Anderson Cancer Center
ClinicalTrials.gov Identifier:
NCT00848289
First received: February 19, 2009
Last updated: April 24, 2017
Last verified: April 2017
February 19, 2009
April 24, 2017
February 10, 1998
August 2017   (Final data collection date for primary outcome measure)
Comparison of mutagen sensitivity susceptibility assays that quantifies the number of lymphocytic chromatid breaks induced by in vitro exposure to bleomycin and the number of breaks induced by in vitro exposure to a tobacco carcinogen [ Time Frame: After last subject has completed the study, up to 5 years ]
Mutagen sensitivity as measured by quantifying the number of lymphocytic chromatid breaks and comet tail moments induced by in vitro exposure to bleomycin (a radiomimetic agent) and benzo[a]pyrene diol epoxide (BPDE, a tobacco carcinogen) in bladder cancer cases in comparison to data for controls
To assess both cohorts, two mutagen sensitivity susceptibility assays that quantifies the number of lymphocytic chromatid breaks induced by in vitro exposure to bleomycin and the number of breaks induced by in vitro exposure to a tobacco carcinogen. [ Time Frame: After last subject has completed the study ]
Complete list of historical versions of study NCT00848289 on ClinicalTrials.gov Archive Site
  • Frequencies of polymorphisms in those genes that regulate the metabolism of carcinogens in tobacco smoke [ Time Frame: After the last subject completes the study, up to 5 years ]
  • Associations between the cytogenetic, molecular components and epidemiologic covariates (age, sex, ethnicity, cigarette smoking status, alcohol use, dietary intake, and family history of cancer) in risk of bladder cancer [ Time Frame: After the last subject has completed the study, up to 5 years per individiual participation ]
  • To determine in both cohorts, the frequencies of polymorphisms in those genes that regulate the metabolism of carcinogens in tobacco smoke. [ Time Frame: After the last subject completes the study ]
  • To explore the associations between the cytogenetic, molecular components and epidemiologic covariates (age, sex, ethnicity, cigarette smoking status, alcohol use, dietary intake, and family history of cancer) in risk of bladder cancer. [ Time Frame: After the last subject has completed the study ]
Not Provided
Not Provided
 
Genetic Susceptibility to Bladder Cancer
Genetic Susceptibility to Bladder Cancer: A Molecular Epidemiology Approach
This clinical research study will identify biologic and lifestyle factors which increase a person's risk of developing specific cancer. Researchers propose to conduct a case-control study examining interindividual differences in susceptibility to tobacco carcinogenesis as predictors of bladder cancer risk. We will measure susceptibility to tobacco carcinogenesis and this will include studies of the genetic modulation of carcinogen activation and detoxification and of chromosome sensitivity to tobacco mutagens.
Researchers propose to conduct a case-control study examining interindividual differences in susceptibility to tobacco carcinogenesis as predictors of bladder cancer risk. We will measure susceptibility to tobacco carcinogenesis and this will include studies of the genetic modulation of carcinogen activation and detoxification and of chromosome sensitivity to tobacco mutagens.
Observational
Observational Model: Other
Time Perspective: Prospective
Not Provided
Retention:   Samples Without DNA
Description:
blood (about 40 cc or 8 teaspoons), urine
Non-Probability Sample
Any patient who have been diagnosed with bladder cancer or who is healthy is eligible to participate without regard to age, sex, or ethnicity.
Bladder Cancer
Behavioral: Interviews
Data collected by personal interview for Epidemiology and Nutrition Questionnaires, with personal and follow-up telephone interviews.
Participants with Bladder Cancer
Patients diagnosed with superficial or muscle-invasive bladder cancer. Specimens, personal and follow-up telephone interviews will be collected and conducted.
Intervention: Behavioral: Interviews
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruiting
4500
August 2018
August 2017   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Subject has a histologically confirmed diagnosis of superficial or muscle-invasive bladder cancer
  • Subject is a Texas resident.
  • Subject can understand English or a qualified translator is available for the interview.
  • Subjects of any age, gender, or ethnicity are eligible to participate in the study.
  • Subject consents to participate in the study.

Exclusion Criteria:

  • Subject has had prior treatment with systemic chemotherapy or radiotherapy in the past 6 months.
  • Subject has been diagnosed with superficial or muscle-invasive bladder cancer more than twelve months ago.
Sexes Eligible for Study: All
Child, Adult, Senior
Yes
Contact: Xifeng Wu, MD 713-792-3020 xwu@mdanderson.org
Contact: Tao T Le, Program Director, Epidemiology tle@mdanderson.org
United States
 
 
NCT00848289
LAB98-040
LAB98-040 ( Other Identifier: MD Anderson Cancer Center )
5P50CA091846-14 ( U.S. NIH Grant/Contract )
H-8577 ( Other Identifier: Baylor College of Medicine )
No
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Not Provided
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
National Cancer Institute (NCI)
Principal Investigator: Xifeng Wu, MD M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
April 2017

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP